Comparison of Bausch + Lomb Eye Supplements
Bausch + Lomb divides its ocular supplements into two main categories, each serving a different eye health need.
1. Ocuvite Eye Vitamins (General Eye Health)
Ocuvite products are generally recommended for overall, daily eye health and wellness across adult age groups. They are designed to replenish essential nutrients that may be lost as you age or that may be lacking in a typical diet.
| Ocuvite Product Example | Primary Focus | Key Nutrients |
| Ocuvite Eye Health Formula | General eye health support. | Lutein, Zeaxanthin, Omega-3, Vitamins C & E, Zinc, Copper. |
| Ocuvite Adult 50+ | General support for aging eyes. | Optimal blend of Lutein, Zeaxanthin, Omega-3, antioxidants, and is enhanced with Vitamin D. |
| Ocuvite Blue Light | Filtering light from digital devices. | Higher levels of Lutein and Zeaxanthin to shield eyes from blue light. |
2. PreserVision AREDS 2 Formula (Targeted for AMD)
PreserVision products, particularly those containing the AREDS 2 Formula, are for individuals with moderate-to-advanced Age-Related Macular Degeneration (AMD), as advised by a doctor.
-
Clinically Proven: The PreserVision AREDS 2 formula exactly matches the combination of vitamins and minerals proven in the National Eye Institute's (NEI) AREDS 2 clinical trial to help reduce the risk of progression in patients with moderate-to-advanced AMD.
-
Key High-Dose Nutrients (AREDS 2 Formula): High-dose Vitamin C, Vitamin E, Zinc, Copper, Lutein (10 mg), and Zeaxanthin (2 mg).
-
Beta-Carotene Free: The AREDS 2 formula specifically replaces Beta-Carotene with Lutein and Zeaxanthin, making it the recommended choice for former or current smokers, who should avoid Beta-Carotene.
Key Difference in Purpose
| Product Line | Primary Goal | Formula Match |
| Ocuvite | General maintenance and daily nutrient replenishment. | Does not match the specific high-dose formula of the AREDS 2 study. |
| PreserVision AREDS 2 | Reduce the risk of AMD progression. | Exactly matches the formula clinically proven in the AREDS 2 study. |